• QPRT, P2Y11 Signaling, and Breast Cancer Invasion

  2026-10-06

  Liu et al. linked elevated quinolinate phosphoribosyltransferase (QPRT) with breast cancer invasiveness and identified myosin light chain phosphorylation as a downstream feature of this phenotype. Their complementary genetic and pharmacological evidence implicates purinergic P2Y11 signaling, while also leaving important questions about receptor specificity, molecular intermediates, and clinical applicability.

• Spirocyclic POM Analogues Target MmpL3 in TB

  2026-10-06

  A 2024 Bioorganic Chemistry study developed spirocyclic phenyl oxazole methyl (POM) analogues and identified compound 5c as a potent inhibitor of Mycobacterium tuberculosis in vitro. Its activity across drug-susceptible and resistant clinical isolates, together with spontaneous-mutant and docking evidence implicating MmpL3, supports the chemotype as a promising starting point for anti-tuberculosis discovery, while remaining preclinical.

• AAL-993: VEGF Receptor Inhibitor Evidence

  2026-10-05

  AAL-993 is a selective VEGF receptor inhibitor with reported nanomolar activity against VEGFR-1, VEGFR-2, and VEGFR-3. Its preclinical evidence supports tumor angiogenesis research and melanoma models, but it does not establish clinical efficacy or a validated role in glioma biology.

• Saikosaponins Target Smoothened in Medulloblastoma

  2026-10-05

  A 2022 study found that saikosaponins B1 and D reduced Hedgehog pathway activity and medulloblastoma allograft growth, with evidence pointing to Smoothened as their functional pathway target. The work is notable because it combined reporter assays, downstream genetic controls, and in vivo tumor modeling, while still leaving direct binding, pharmacokinetics, and clinical applicability unresolved.

• Tivozanib: Reading Cancer Drug Responses

  2026-10-04

  Tivozanib and AV-951 are examined through a response-phenotyping framework that separates pathway inhibition, growth arrest, and cell death. Drawing on Schwartz’s dissertation, this article explains why potency and viability should not be treated as interchangeable evidence.

• Tivozanib (AV-951): Evidence and Research Context

  2026-10-03

  A source-grounded overview of Tivozanib (AV-951), covering VEGFR signaling pathway inhibition, renal cell carcinoma research, response metrics, evidence quality, and translational limitations.

• Tofacitinib Citrate for JAK-STAT Research

  2026-10-02

  Tofacitinib citrate enables dose-resolved studies of JAK-STAT signaling, lymphocyte behavior, and inflammatory cytokine responses. A concentration-aware workflow can distinguish useful immune modulation from endothelial stress, especially when extending experiments into vascular inflammation models.

• ABT-199: Mapping BCL-2 Dependency in Apoptosis

  2026-10-01

  ABT-199, also known as Venetoclax, is a precise probe of BCL-2 dependence rather than a nonspecific apoptosis trigger. This guide connects selective pharmacology with assay design, MCL-1-mediated resistance, and hematologic malignancy research.

• Entamoeba Peroxiredoxin Activates Macrophage Autophagy

  2026-10-01

  The reference study shows that recombinant Entamoeba histolytica peroxiredoxin activates autophagy and contributes to macrophage cytotoxicity through a pathway that depends largely on TLR4–TRIF signaling. Its combination of macrophage and mouse models, imaging, immunoblotting, RNA interference, and protein-domain analysis identifies a parasite antioxidant enzyme as a host-directed immunomodulatory factor.

• Cucurbitacin I Workflows for STAT3 Research

  2026-09-30

  Cucurbitacin I, also known as JSI-124, offers a pathway-focused way to connect STAT3 signaling with proliferation, apoptosis, invasion, and treatment response. This practical guide combines benchmark conditions, orthogonal assays, formulation guidance, and carefully bounded lessons from a human pacemaker assembloid study.

• Testosterone Bounce in Degarelix-Treated Prostate Cancer

  2026-09-30

  A 2024 study identified testosterone bounce—a rise above 20 ng/dL after testosterone falls below that threshold—as a prognostic marker in patients receiving degarelix for prostate cancer. The association with overall and cancer-specific survival, but not progression-free survival, suggests that longitudinal testosterone kinetics may complement PSA-based assessment while requiring prospective validation.

• Tofacitinib Citrate in Immune & Vascular Assays

  2026-09-29

  Tofacitinib citrate enables nanomolar JAK3-focused immune assays while also supporting concentration-aware studies of cytokine-stressed endothelial cells. This guide connects lymphocyte and differentiation workflows with vascular readouts, emphasizing dose selection, multi-endpoint validation, and troubleshooting.

• ABT-199 (Venetoclax) Research Workflow

  2026-09-29

  Build more informative BCL-2 dependency studies with ABT-199 (Venetoclax), from dose-response design to orthogonal mitochondrial apoptosis readouts. The workflow also shows how the compound can support combination studies in non-Hodgkin lymphoma and acute myelogenous leukemia models without confusing BCL-2 dependence with resistance driven by other survival proteins.

• MK-1775: Wee1 Kinase Inhibitor Guide

  2026-09-28

  MK-1775 is an ATP-competitive Wee1 kinase inhibitor that blocks inhibitory CDK1 Tyr15 phosphorylation and abrogates the G2 DNA damage checkpoint. Product evidence supports its use in mechanistic cancer research, especially combination studies involving p53-deficient tumor models and DNA-damaging agents.

• QPRT Promotes Breast Cancer Invasion via MLC Phosphorylation

  2026-09-28

  Liu and colleagues link elevated quinolinate phosphoribosyltransferase (QPRT) to breast cancer cell migration and invasion, and identify myosin light chain phosphorylation as a downstream correlate. Their genetic and inhibitor-based experiments implicate P2Y11-associated signaling, while leaving the biochemical connection between QPRT activity and purinergic signaling open for further study.

7964 records 1/531 page Next 12345 下5页 Last page